MCID: LCL006
MIFTS: 63

Localized Scleroderma

Categories: Bone diseases, Genetic diseases, Immune diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Localized Scleroderma

MalaCards integrated aliases for Localized Scleroderma:

Name: Localized Scleroderma 12 53 59 37 15 73
Morphea 12 53 55 73
Localized Fibrosing Scleroderma 53 59
Scleroderma, Circumscribed or Localized 12
Circumscribed Scleroderma 12
Scleroderma, Localized 53
Localised Morphoea 12
Localized Morphea 12

Characteristics:

Orphanet epidemiological data:

59
localized scleroderma
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

Orphanet: 59  
Rare skin diseases


External Ids:

Disease Ontology 12 DOID:8472
ICD10 33 L94.0
ICD9CM 35 701.0
MeSH 44 D012594
NCIt 50 C72069
SNOMED-CT 68 90424004
Orphanet 59 ORPHA90289
UMLS via Orphanet 74 C0036420
ICD10 via Orphanet 34 L94.0
MESH via Orphanet 45 D012594
KEGG 37 H01493

Summaries for Localized Scleroderma

NIH Rare Diseases : 53 Localized scleroderma is characterized by thickening of the skin from excessive collagen deposits. Collagen is a protein normally present in our skin that provides structural support. However, when too much collagen is made, the skin becomes stiff and hard. Localized types of scleroderma are those limited to the skin and related tissues and, in some cases, the muscle below. Internal organs are not affected by localized scleroderma, and localized scleroderma can never progress to the systemic form of the disease. Often, localized conditions improve or go away on their own over time, but the skin changes and damage that occur when the disease is active can be permanent. For some people, localized scleroderma is serious and disabling. There are two generally recognized types of localized scleroderma: morphea and linear.  

MalaCards based summary : Localized Scleroderma, also known as morphea, is related to central nervous system vasculitis and psoriasis, and has symptoms including pruritus and exanthema. An important gene associated with Localized Scleroderma is MMP1 (Matrix Metallopeptidase 1), and among its related pathways/superpathways are Pathways in cancer and Degradation of the extracellular matrix. The drugs Lidocaine and Vaccines have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and thyroid, and related phenotypes are arthralgia and lipoatrophy

Wikipedia : 76 Morphea, also called localized scleroderma or circumscribed scleroderma, is a form of scleroderma that... more...

Related Diseases for Localized Scleroderma

Diseases in the Systemic Scleroderma family:

Scleroderma, Familial Progressive Localized Scleroderma

Diseases related to Localized Scleroderma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 297)
# Related Disease Score Top Affiliating Genes
1 central nervous system vasculitis 29.7 IL6 TNF
2 psoriasis 29.7 DEFB4A IL6 SELE TNF
3 arthritis 29.6 IL6 MMP1 MMP13 TGFB1 TNF
4 polyarteritis nodosa 29.4 IL6 SELE SMAD3
5 vasculitis 29.3 SELE TNF VCAM1
6 osteoarthritis 29.3 IL6 MMP1 MMP13 TGFB1 TNF
7 systemic lupus erythematosus 29.1 IL6 SELE TGFB1 TNF VCAM1
8 dermatitis, atopic 29.0 DEFB4A SELE TNF VCAM1
9 rheumatoid arthritis 28.7 IL6 MMP1 MMP13 SELE TGFB1 TNF
10 systemic scleroderma 12.1
11 linear scleroderma 11.6
12 morpheaform basal cell carcinoma 11.6
13 facial hemiatrophy 11.4
14 hemifacial atrophy, progressive 11.4
15 atrophoderma of pierini and pasini 11.3
16 reynolds syndrome 10.4
17 scleroderma, familial progressive 10.3
18 fibromatosis, gingival, 1 10.2 MMP1 TGFB1
19 periodontitis, chronic 10.2 IL6 MMP1
20 diabetic foot ulcers 10.2 IL6 TGFB1
21 kashin-beck disease 10.2 MMP1 TNF
22 scorpion envenomation 10.2 IL6 TNF
23 bone chondrosarcoma 10.2 MMP1 MMP13
24 leukomalacia 10.2 IL6 TNF
25 odontogenic myxoma 10.2 DCN MMP1
26 angioimmunoblastic lymphadenopathy with dysproteinemia 10.2 IL6 TNF
27 streptococcal toxic-shock syndrome 10.2 IL6 TNF
28 clonorchiasis 10.2 TGFB1 TNF
29 juvenile ankylosing spondylitis 10.2 IL6 TNF
30 cardiogenic shock 10.2 IL6 TNF
31 null-cell leukemia 10.2 IL6 TNF
32 retinitis pigmentosa 55 10.2 IL6 TNF
33 anca-associated vasculitis 10.2 IL6 TNF
34 hypertrophic scars 10.2 SMAD3 TGFB1
35 glossitis 10.2 IL6 TNF
36 anterior uveitis 10.2 IL6 TNF
37 acute vascular insufficiency of intestine 10.2 IL6 TNF
38 osteosclerotic myeloma 10.2 IL6 TNF
39 poems syndrome 10.2 IL6 TNF
40 periapical periodontitis 10.2 IL6 TNF
41 autoimmune gastritis 10.2 IL6 TNF
42 meconium aspiration syndrome 10.2 IL6 TNF
43 burning mouth syndrome 10.2 IL6 TNF
44 stachybotrys chartarum 10.2 IL6 TNF
45 louse-borne relapsing fever 10.2 IL6 TNF
46 endometrial disease 10.1 IL6 TNF
47 dupuytren contracture 10.1 DCN TGFB1
48 gingival disease 10.1 IL6 MMP1 TGFB1
49 keloids 10.1 MMP1 SMAD3 TGFB1
50 listeriosis 10.1 IL6 TNF

Comorbidity relations with Localized Scleroderma via Phenotypic Disease Network (PDN):


Systemic Scleroderma Vulva Cancer

Graphical network of the top 20 diseases related to Localized Scleroderma:



Diseases related to Localized Scleroderma

Symptoms & Phenotypes for Localized Scleroderma

Human phenotypes related to Localized Scleroderma:

59 32 (show all 16)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 arthralgia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002829
2 lipoatrophy 59 32 occasional (7.5%) Occasional (29-5%) HP:0100578
3 skeletal muscle atrophy 59 32 frequent (33%) Frequent (79-30%) HP:0003202
4 myalgia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003326
5 split hand 59 32 occasional (7.5%) Occasional (29-5%) HP:0001171
6 hemiatrophy of upper limb 59 32 occasional (7.5%) Occasional (29-5%) HP:0100558
7 flexion contracture of toe 59 32 occasional (7.5%) Occasional (29-5%) HP:0005830
8 hyperpigmentation of the skin 59 32 hallmark (90%) Very frequent (99-80%) HP:0000953
9 hypopigmentation of the skin 59 32 hallmark (90%) Very frequent (99-80%) HP:0001010
10 stiff skin 59 32 hallmark (90%) Very frequent (99-80%) HP:0030053
11 cigarette-paper scars 59 32 hallmark (90%) Very frequent (99-80%) HP:0001073
12 scarring alopecia of scalp 59 32 occasional (7.5%) Occasional (29-5%) HP:0004552
13 hemiatrophy of lower limb 59 32 occasional (7.5%) Occasional (29-5%) HP:0100557
14 flexion contracture 59 Occasional (29-5%)
15 hemiatrophy 59 Occasional (29-5%)
16 dermal atrophy 59 Very frequent (99-80%)

UMLS symptoms related to Localized Scleroderma:


pruritus, exanthema

MGI Mouse Phenotypes related to Localized Scleroderma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.01 DCN IL6 MMP13 SELE SMAD3 TGFB1
2 cardiovascular system MP:0005385 9.98 IL6 MMP13 SELE SMAD3 TGFB1 TNF
3 growth/size/body region MP:0005378 9.97 DCN IL6 MMP13 SELE SMAD3 TGFB1
4 homeostasis/metabolism MP:0005376 9.97 DCN IL6 MMP1 MMP13 SELE SMAD3
5 immune system MP:0005387 9.86 DCN IL6 MMP1 SELE SMAD3 TGFB1
6 integument MP:0010771 9.7 DCN IL6 MMP13 SELE SMAD3 TGFB1
7 neoplasm MP:0002006 9.43 DCN IL6 MMP1 SMAD3 TGFB1 TNF
8 vision/eye MP:0005391 9.1 DCN IL6 SELE SMAD3 TGFB1 TNF

Drugs & Therapeutics for Localized Scleroderma

Drugs for Localized Scleroderma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 176)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3 137-58-6 3676
2 Vaccines Phase 4
3 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Diuretics, Potassium Sparing Phase 4,Phase 2,Phase 3
5 Anti-Arrhythmia Agents Phase 4,Phase 2,Phase 3
6 Sodium Channel Blockers Phase 4,Phase 2,Phase 3
7 Anesthetics Phase 4,Phase 2,Phase 3,Not Applicable
8 Anesthetics, Local Phase 4,Phase 2,Phase 3
9 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Not Applicable
10 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
11
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
12
Glucosamine Approved, Investigational Phase 2, Phase 3 3416-24-8 439213
13
Lenograstim Approved, Investigational Phase 3 135968-09-1
14
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
15
Tadalafil Approved, Investigational Phase 3 171596-29-5 110635
16
Acetylcholine Approved Phase 3 51-84-3 187
17
Omeprazole Approved, Investigational, Vet_approved Phase 3 73590-58-6 4594
18
Alginic acid Approved, Investigational Phase 3 9005-32-7
19
Domperidone Approved, Investigational, Vet_approved Phase 3,Not Applicable 57808-66-9 3151
20
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
21
Bosentan Approved, Investigational Phase 2, Phase 3 147536-97-8 104865
22
Macitentan Approved Phase 2, Phase 3 441798-33-0
23
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
24 Antirheumatic Agents Phase 3,Phase 2,Phase 1
25 Interferon Inducers Phase 3
26 interferons Phase 3,Phase 1
27 Adjuvants, Immunologic Phase 3
28 Phosphodiesterase 5 Inhibitors Phase 3
29 Citrate Phase 3
30 Phosphodiesterase Inhibitors Phase 3,Phase 2
31 Vasodilator Agents Phase 3,Phase 2
32 Sildenafil Citrate Phase 3,Not Applicable 171599-83-0
33 Fibrinolytic Agents Phase 2, Phase 3
34 Hypoglycemic Agents Phase 2, Phase 3
35 Hypolipidemic Agents Phase 2, Phase 3
36 Antimetabolites Phase 2, Phase 3,Phase 1
37 Pharmaceutical Solutions Phase 2, Phase 3,Phase 3,Not Applicable
38 Glucuronyl glucosamine glycan sulfate Phase 2, Phase 3
39 Anticoagulants Phase 2, Phase 3,Phase 3,Phase 1
40 Lipid Regulating Agents Phase 2, Phase 3
41 Alkylating Agents Phase 3,Phase 2,Phase 1
42 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
43 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
44 Calcium, Dietary Phase 3,Phase 2,Phase 1,Early Phase 1
45 Chelating Agents Phase 3
46 Neuromuscular Agents Phase 3
47 Botulinum Toxins Phase 3
48 abobotulinumtoxinA Phase 3
49 Neurotransmitter Agents Phase 3
50 Acetylcholine Release Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 90)
# Name Status NCT ID Phase Drugs
1 Influenza Vaccination in Patients With Scleroderma Unknown status NCT01002508 Phase 4
2 Efficacy and Safety of PLACENTEX ® i.m. in Patients With Scleroderma Diseases Recruiting NCT03388255 Phase 4 Polydeoxyribonucleotides
3 Pain Outcomes Following Intralesional Corticosteroid Injections Not yet recruiting NCT03630198 Phase 4 Corticosteroid with lidocaine;Corticosteroid with normal saline
4 Imiquimod in Children With Plaque Morphea Completed NCT00147771 Phase 3 Imiquimod 5% cream
5 Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY Completed NCT01295736 Phase 3 Sildenafil;placebo
6 Effectiveness and Safety of Lidocaine for Scleroderma Completed NCT00740285 Phase 2, Phase 3 Lidocaine 2% without vessel constrictor
7 High Dose Cyclophosphamide for Treatment of Scleroderma Completed NCT00501995 Phase 3 IV Cyclophosphamide
8 A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Completed NCT01117298 Phase 3 Tadalafil;Placebo
9 Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis Completed NCT01347008 Phase 3 Sildenafil citrate;Placebo (Sugar pill)
10 Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome Completed NCT02165111 Phase 3 Onabotulinumtoxin A;sterile saline solution
11 Gastroesophageal Reflux Treatment in Scleroderma Completed NCT01878526 Phase 3 Alginic acid;placebo (for domperidone);Domperidone;placebo (of alginic acid)
12 Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma Completed NCT00070590 Phase 2, Phase 3 Bosentan
13 Scleroderma Lung Disease Completed NCT00004563 Phase 3 Cyclophosphamide;Placebo
14 CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH Recruiting NCT03726398 Phase 2, Phase 3 Opsumit 10 Mg Tablet
15 Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study Withdrawn NCT00230373 Phase 3 imiquimod 5% cream (Aldara)
16 A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy Unknown status NCT00936546 Phase 2 Rituximab
17 Efficacy and Safety of Imatinib in Scleroderma Completed NCT00479934 Phase 2 imatinib mesylate
18 Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix Completed NCT00129428 Phase 1, Phase 2
19 Effect of Bosentan in Scleroderma Renal Crisis Completed NCT01241383 Phase 2 Bosentan
20 Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine Completed NCT00775463 Phase 2 treprostinil diethanolamine;placebo
21 Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis Completed NCT00764309 Phase 1, Phase 2 dasatinib
22 A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma) Completed NCT00442611 Phase 1, Phase 2 Abatacept;Placebo
23 Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma Completed NCT00278525 Phase 2 standard of care
24 IL1-TRAP, Rilonacept, in Systemic Sclerosis Completed NCT01538719 Phase 1, Phase 2 Rilonacept
25 Oral Type I Collagen for Relieving Scleroderma Completed NCT00005675 Phase 2 Oral bovine type I collagen;Placebo
26 Riociguat in Scleroderma Associated Digital Ulcers Completed NCT02915835 Phase 2 Riociguat;Placebo
27 Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital Ulcers Completed NCT02801305 Phase 2 Diltiazem Gel 2%;Nitroglycerin Ointment 2%;Vaseline
28 Zibotentan Better Renal Scleroderma Outcome Study Completed NCT02047708 Phase 2 Zibotentan
29 Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II) Completed NCT00883129 Phase 2 Mycophenolate mofetil;Cyclophosphamide;Placebo
30 Psychological Treatments for Scleroderma Completed NCT00007267 Phase 2
31 Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease Completed NCT01559129 Phase 2 Pomalidomide (CC-4047);Placebo
32 A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma Recruiting NCT03740724 Phase 1, Phase 2 veledimex
33 Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea Recruiting NCT03351114 Phase 2 Crisaborole
34 Pirfenidone Plus M-DDO Gel in Moderate and Severe Acne Recruiting NCT03076320 Phase 1, Phase 2
35 Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma Recruiting NCT02370784 Phase 2 atorvastatin;Placebo
36 Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells Recruiting NCT02213705 Phase 1, Phase 2
37 Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate Recruiting NCT03221257 Phase 2 Pirfenidone (PFD);Placebo (Plac);Mycophenolate Mofetil (MMF)
38 Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension Recruiting NCT02682511 Phase 2 Oral Ifetroban;Oral Placebo
39 Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma Terminated NCT01545427 Phase 2 Imatinib mesylate
40 Placebo Controlled Trial of Bosentan in Scleroderma Patients Terminated NCT00377455 Phase 2 Bosentan;Placebo
41 A Study of the Safety and Tolerability of MEDI-551 in Scleroderma Completed NCT00946699 Phase 1
42 A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma Completed NCT00930683 Phase 1 MEDI-546;MEDI-546;MEDI-546;MEDI-546;MEDI-546;MEDI-546;MEDI-546;MEDI-546;MEDI-546
43 Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma Completed NCT02426229 Phase 1 dabigatran etexilate
44 Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients Terminated NCT00040651 Phase 1 Fludarabine;Cyclophosphamide;Thymoglobulin
45 Comparative Effectiveness Trial in the Treatment of Pediatric Plaque Morphea Withdrawn NCT02680717 Phase 1 Clobetasol;Calcipotriene;Tacrolimus
46 Fractional Carbon Dioxide Laser Versus UVA 1 in Treatment of Localized Scleroderma Unknown status NCT02002897 Not Applicable
47 Genetic Variants in Linear Localized Scleroderma Unknown status NCT02222038 Not Applicable
48 Treatment Study Comparing UVA-1 Phototherapy Versus Placebo Treatment for Morphea Unknown status NCT01799174 Not Applicable
49 Empirical Comparative Study of Variation Blood Level Antibody Vitamin D at Scleroderma (SSc) Patients Compared Healthy Peoples Unknown status NCT01553890 Not Applicable
50 Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea. Completed NCT00812188 Not Applicable

Search NIH Clinical Center for Localized Scleroderma

Genetic Tests for Localized Scleroderma

Anatomical Context for Localized Scleroderma

MalaCards organs/tissues related to Localized Scleroderma:

41
Skin, Bone, Thyroid, Lung, Heart, Prostate, T Cells

Publications for Localized Scleroderma

Articles related to Localized Scleroderma:

(show top 50) (show all 909)
# Title Authors Year
1
Collagen-enriched serpiginous skin lesion in a cat resembling the linear form of localized scleroderma in humans. ( 29794370 )
2018
2
Impact of a new simplified disability scoring system for adult patients with localized scleroderma. ( 29369402 )
2018
3
Development of minimum standards of care for juvenile localized scleroderma. ( 29728839 )
2018
4
Diagnostic criteria, severity classification and guidelines of localized scleroderma. ( 29687475 )
2018
5
Supportive Use of Adipose-Derived Stem Cells in Cell-Assisted Lipotransfer for Localized Scleroderma. ( 29794702 )
2018
6
Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma. ( 29077971 )
2018
7
Detection of autoimmune antibodies in localized scleroderma by synthetic oligonucleotide antigens. ( 29641558 )
2018
8
Abatacept Improves Skin-score and Reduces Lesions in Patients with Localized Scleroderma: A Case Series. ( 29313055 )
2018
9
Disease course and long-term outcome of juvenile localized scleroderma: Experience from a single pediatric rheumatology Centre and literature review. ( 29729451 )
2018
10
Localized scleroderma occurring after treatment of chronic hepatitis C with sofosbuvir and ribavirin. ( 29863777 )
2018
11
Comparing ultraviolet light A photo(chemo)therapy with Methotrexate protocol in childhood localized scleroderma: Evidence from systematic review and meta-analysis approach. ( 29655520 )
2018
12
From Localized Scleroderma to Systemic Sclerosis: Coexistence or Possible Evolution. ( 29666638 )
2018
13
Reliability of LoSCAT score for activity and tissue damage assessment in a large cohort of patients with Juvenile Localized Scleroderma. ( 29914516 )
2018
14
Giant morphea-form basal cell carcinoma of the umbilicus: Successful debulking with vismodegib. ( 29760872 )
2018
15
Comorbidity of localized scleroderma and primary biliary cholangitis. ( 30395408 )
2018
16
Fluoroscopy-induced chronic radiation dermatitis masquerading as morphea: A diagnostic pitfall. ( 30004062 )
2018
17
Localized scleroderma causing enophthalmos: A rare entity. ( 30355873 )
2018
18
Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib. ( 29984277 )
2018
19
Granulomatous fasciitis followed by morphea profunda: Is granulomatous fasciitis part of a spectrum of deep morphea? A case report and review of the literature. ( 30147873 )
2018
20
Morphea «En Coup De Sabre» at the Site of Healed Herpes Zoster Ophthalmicus. ( 30201544 )
2018
21
Assessing the response of morphea and limited scleroderma to tranilast: a small prospective study comparing topical corticosteroids to a combination of topical corticosteroids and tranilast. ( 30013378 )
2018
22
Localized Scleroderma of the Head and Face Area: A Retrospective Cross-sectional Study of 96 Patients from 5 German Tertiary Referral Centres. ( 29507998 )
2018
23
Juvenile Localized Scleroderma with Hyaline Deposits in the Renal Arteriole. ( 29805370 )
2018
24
Erratum to "From Localized Scleroderma to Systemic Sclerosis: Coexistence or Possible Evolution". ( 29973952 )
2018
25
Detecting and quantifying activity/inflammation in localized scleroderma with thermal imaging. ( 30030915 )
2018
26
Scleroderma in Children and Adolescents: Localized Scleroderma and Systemic Sclerosis. ( 30031497 )
2018
27
Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) adapted for use in adult patients: report from an initial validation study. ( 30217204 )
2018
28
New Features for Measuring Disease Activity in Pediatric Localized Scleroderma. ( 30219769 )
2018
29
Progranulin overproduction due to constitutively activated c-Abl/PKC-δ/Fli1 pathway contributes to the resistance of dermal fibroblasts to the anti-fibrotic effect of tumor necrosis factor-α in localized scleroderma. ( 30268392 )
2018
30
Prediction of disease relapse in a cohort of paediatric patients with localized scleroderma. ( 30315656 )
2018
31
A case of juvenile localized scleroderma with anti-topoisomerase I antibody. ( 30442630 )
2018
32
Comparison of 2-D shear wave elastography with clinical score in localized scleroderma: A new method to increase the diagnostic accuracy. ( 30506714 )
2018
33
Morphea associated with primary biliary cirrhosis and Waldenstrom macroglobulinemia: Response to rituximab. ( 30246126 )
2018
34
Morphea and systemic sclerosis are associated with an increased risk of melanoma and non-melanoma skin cancer. ( 30352282 )
2018
35
Early morphea simulating patch-stage mycosis fungoides in two cases. ( 29760873 )
2018
36
Facial solitary morphea profunda presenting with painful trigeminal neuropathy: A case report. ( 30213201 )
2018
37
Antibodies against antigens related to scleroderma in a cohort of patients with morphea. ( 27706114 )
2018
38
Bee venom acupuncture for circumscribed morphea in a patient with systemic sclerosis: A case report. ( 30544415 )
2018
39
Postirradiation Morphea in Patients With Breast Cancer: Possible Association With Other Autoimmune Diseases. ( 30389122 )
2018
40
The efficacy of methotrexate in the treatment of en coup de sabre (linear morphea subtype). ( 28604132 )
2018
41
Wood's lamp as a tool in the evaluation of morphea. ( 28993235 )
2018
42
Orthopedic complications of linear morphea: Implications for early interdisciplinary care. ( 29119592 )
2018
43
Discordance of pediatric morphea treatment by pediatric dermatologists. ( 29165838 )
2018
44
Reactivity to anti-RNA polymerase III antibody and nailfold capillary changes in patient with generalized morphea combined with multiple autoimmune disorders. ( 29171400 )
2018
45
Regarding "Transcriptional and Cytokine Profiles Identify CXCL9 as a Biomarker of Disease Activity in Morphea". ( 29246801 )
2018
46
Morphea in Childhood: An Update. ( 29248149 )
2018
47
Skin mapping for the classification of generalized morphea. ( 29332706 )
2018
48
Inflammatory morphea presenting as a hemifacial acquired port-wine stain. ( 29449213 )
2018
49
Trichoscopic Features of Linear Morphea on the Scalp. ( 29457011 )
2018
50
Inflammatory arthritis in pediatric patients with morphea. ( 29535035 )
2018

Variations for Localized Scleroderma

Expression for Localized Scleroderma

Search GEO for disease gene expression data for Localized Scleroderma.

Pathways for Localized Scleroderma

Pathways related to Localized Scleroderma according to GeneCards Suite gene sharing:

(show all 49)
# Super pathways Score Top Affiliating Genes
1 12.72 IL6 MMP1 SMAD3 TGFB1
2
Show member pathways
12.62 DCN MMP1 MMP13 TGFB1 VCAM1
3
Show member pathways
12.47 IL6 SMAD3 TGFB1 TNF
4 12.28 IL6 SMAD3 TGFB1 TNF VCAM1
5 12.18 DCN TGFB1 TNF
6
Show member pathways
12.16 DEFB4A IL6 MMP1 MMP13 TNF
7
Show member pathways
12.13 MMP1 SELE TGFB1
8 12.13 IL6 TGFB1 TNF
9
Show member pathways
12.11 IL6 TGFB1 TNF
10
Show member pathways
12.08 DEFB4A IL6 TNF
11 12.06 IL6 SMAD3 TGFB1
12
Show member pathways
12.02 IL6 SMAD3 TGFB1
13 11.99 SELE TNF VCAM1
14
Show member pathways
11.98 IL6 SMAD3 TGFB1
15 11.98 IL6 MMP1 SMAD3 TGFB1 TNF
16 11.96 IL6 TGFB1 VCAM1
17 11.96 IL6 SMAD3 TGFB1 TNF
18 11.95 MMP1 SMAD3 TGFB1
19
Show member pathways
11.94 IL6 SMAD3 TGFB1 TNF
20 11.9 IL6 TGFB1 TNF
21 11.85 IL6 SELE TNF VCAM1
22 11.84 IL6 SMAD3 TGFB1
23
Show member pathways
11.8 MMP1 MMP13 TNF
24 11.78 IL6 TGFB1 TNF
25
Show member pathways
11.76 IL6 SMAD3 TGFB1
26 11.75 IL6 MMP1 TGFB1 TNF
27 11.71 IL6 MMP1 TGFB1 TNF VCAM1
28 11.7 IL6 MMP1 SELE
29 11.68 DCN SMAD3 TGFB1 TNF
30 11.65 IL6 TGFB1 TNF
31 11.63 IL6 TGFB1 TNF
32 11.57 IL6 TGFB1 TNF
33 11.52 SMAD3 TGFB1 TNF
34 11.41 IL6 SMAD3 TNF
35 11.41 IL6 MMP1 SMAD3 TGFB1
36
Show member pathways
11.35 IL6 MMP1 SELE TNF VCAM1
37 11.27 DCN IL6 MMP1
38 11.19 IL6 TGFB1 TNF
39 11.18 SMAD3 TGFB1
40 11.17 IL6 SELE TNF VCAM1
41 11.1 IL6 SELE SMAD3 TGFB1 TNF VCAM1
42 11.04 IL6 SELE TGFB1 TNF VCAM1
43 11.03 TNF VCAM1
44 11.03 IL6 TNF
45 10.96 IL6 TNF
46 10.93 SMAD3 TGFB1
47 10.89 MMP1 TGFB1
48 10.85 TNF VCAM1
49 10.79 TGFB1 TNF

GO Terms for Localized Scleroderma

Cellular components related to Localized Scleroderma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.76 DCN DEFB1 DEFB4A IL6 MMP1 MMP13
2 extracellular matrix GO:0031012 9.56 DCN MMP1 MMP13 TGFB1
3 extracellular space GO:0005615 9.28 DCN DEFB1 DEFB4A IL6 MMP13 SELE
4 Golgi lumen GO:0005796 9.26 DCN DEFB1 DEFB4A TGFB1

Biological processes related to Localized Scleroderma according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.91 IL6 SMAD3 TGFB1 TNF
2 inflammatory response GO:0006954 9.91 IL6 SELE TGFB1 TNF
3 immune response GO:0006955 9.88 DEFB1 DEFB4A IL6 SMAD3 TNF
4 aging GO:0007568 9.85 DCN TGFB1 VCAM1
5 response to hypoxia GO:0001666 9.83 SMAD3 TGFB1 VCAM1
6 response to lipopolysaccharide GO:0032496 9.83 DCN SELE VCAM1
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.8 IL6 TGFB1 TNF
8 defense response GO:0006952 9.8 DEFB1 DEFB4A TNF
9 positive regulation of DNA-binding transcription factor activity GO:0051091 9.77 IL6 SMAD3 TNF
10 wound healing GO:0042060 9.76 DCN SMAD3 TGFB1
11 leukocyte migration GO:0050900 9.76 MMP1 SELE TGFB1 TNF
12 defense response to Gram-negative bacterium GO:0050829 9.74 DEFB1 DEFB4A IL6
13 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.73 IL6 TGFB1 TNF
14 endoderm development GO:0007492 9.68 SMAD3 TGFB1
15 leukocyte cell-cell adhesion GO:0007159 9.68 SELE VCAM1
16 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.68 SMAD3 TGFB1
17 negative regulation of myoblast differentiation GO:0045662 9.67 TGFB1 TNF
18 negative regulation of neurogenesis GO:0050768 9.67 IL6 TNF
19 positive regulation of protein complex assembly GO:0031334 9.66 TGFB1 TNF
20 cell-cell junction organization GO:0045216 9.65 SMAD3 TGFB1
21 protein import into nucleus, translocation GO:0000060 9.65 TGFB1 TNF
22 cytokine-mediated signaling pathway GO:0019221 9.65 IL6 MMP1 TGFB1 TNF VCAM1
23 calcium-mediated signaling using intracellular calcium source GO:0035584 9.64 DEFB1 VCAM1
24 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.64 SMAD3 TGFB1
25 positive regulation of chemokine production GO:0032722 9.63 IL6 TNF
26 positive regulation of glial cell proliferation GO:0060252 9.62 IL6 TNF
27 extrinsic apoptotic signaling pathway GO:0097191 9.61 SMAD3 TGFB1 TNF
28 lens fiber cell differentiation GO:0070306 9.6 SMAD3 TGFB1
29 negative regulation of lipid storage GO:0010888 9.58 IL6 TNF
30 SMAD protein complex assembly GO:0007183 9.55 SMAD3 TGFB1
31 positive regulation of neuroinflammatory response GO:0150078 9.54 IL6 TNF
32 negative regulation of mitotic cell cycle GO:0045930 9.54 SMAD3 TGFB1 TNF
33 positive regulation of extracellular matrix assembly GO:1901203 9.52 SMAD3 TGFB1
34 regulation of binding GO:0051098 9.51 SMAD3 TGFB1
35 regulation of striated muscle tissue development GO:0016202 9.49 SMAD3 TGFB1
36 defense response to Gram-positive bacterium GO:0050830 9.46 DEFB1 DEFB4A IL6 TNF
37 positive regulation of mononuclear cell migration GO:0071677 9.4 TGFB1 TNF
38 evasion or tolerance of host defenses by virus GO:0019049 9.32 SMAD3 TGFB1
39 leukocyte tethering or rolling GO:0050901 9.13 SELE TNF VCAM1
40 negative regulation of fat cell differentiation GO:0045599 8.92 IL6 SMAD3 TGFB1 TNF
41 positive regulation of transcription by RNA polymerase II GO:0045944 10.07 DCN IL6 SMAD3 TGFB1 TNF

Molecular functions related to Localized Scleroderma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CCR6 chemokine receptor binding GO:0031731 8.96 DEFB1 DEFB4A
2 collagen binding GO:0005518 8.8 DCN MMP13 SMAD3

Sources for Localized Scleroderma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....